Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
FAIL · Does not pass the screen
56.85 USD
Screen close, 2026-10-01 · not a live quote Last reviewed 6 days ago
Screened 2026-10-01 · the tape above runs as of 17:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 56.85 against the desk's fair-value range, base estimate 90.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price56.85 USD
Fair value90.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown56.85+0.0% to today
2026-09-15Read Accumulation66.17-14.1% to today
2026-08-15Read Markup61.32-7.3% to today
2026-07-02Read Accumulation52.04+9.2% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Travere Therapeutics, Inc. holds its Markdown at $56.85. Consolidating, no directional conviction, held for 11 days.
As held on the ledger · 2026-10-01
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 11 days
Price at the screen
$56.85
Valuation
N/A trailing · 10.02 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.06
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
54.32%
Below 33%
Interest-bearing debt is 54.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
37.97%
Below 33%
Interest-bearing cash and securities are 38.0% of assets, above the one-third limit.
Fail
Receivables
28.61%
Below 49%
Money owed to the company is 28.6% of assets, under the 49% limit.
Pass
Revenue purity
2.59%
Below 5%
Only 2.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Travere Therapeutics,'s business is in a permissible area, but its interest-bearing debt is about 54% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-07. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 58.3% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +33% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare disease biotech still burns cash fast
Picture a doctor handing a patient one pill a day that might slow a rare kidney disease. That is the promise Travere is selling. Revenue is rising at 56 percent, the shares trade at just 11.7 times forward earnings, and the ethical screen gives a clean pass. Yet the company still posts a negative 4 percent profit margin and a minus 69 percent return on equity, so the business has yet to prove it can keep the cash flowing once the early launch spending fades.
We pass because the numbers do not add up to a durable edge. An unknown moat, continued losses and heavy reliance on a single product leave too much room for clinical or competitive setbacks. The 23 percent gap between the current price and our fair value looks attractive only if the losses turn into steady profits soon, which the present figures do not confirm.
Risk sits in the usual biotech traps: trial delays, pricing pressure and dilution if cash runs short. Even with fourteen analysts calling it a strong buy, the market is still waiting for proof that growth converts into real earnings. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TVTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$56.85-14.1%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (14 analysts) rates it strong buy, with a mean price target of $54. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (14 analysts) rates it strong buy, with a mean price target of $54.
2026-08-15Markup · changed$61.32+17.8%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 17.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (14 analysts) rates it strong buy, with a mean price target of $54.
2026-07-18Accumulation$52.04+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (14 analysts) rates it strong buy, with a mean price target of $54.
2026-07-03Accumulation$52.04+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$52.04Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
